Danaher Corporation
DHR
$200.14
-0.19%
Danaher Corporation is a global life sciences and diagnostics company that designs and manufactures scientific instruments, consumables, and diagnostic solutions used across biopharmaceutical research, clinical testing, and applied markets, following the late-2023 spin-off of its environmental and applied solutions unit, Veralto. The company is widely regarded as a premier franchise in the medical diagnostics and research tools sector, distinguished by its Danaher Business System (DBS), a lean-management operating framework that has historically driven above-market margin expansion and disciplined capital deployment across a portfolio built through decades of M&A. The current investor narrative is dominated by the integration of the recently announced Masimo acquisition, which analysts have characterized as financially solid but strategically conservative rather than transformative, alongside debate over whether shipment delays in the biotech segment that triggered a sharp single-week selloff represent a temporary logistics issue or a demand warning. Sentiment is further shaped by the stock's significant underperformance versus the S&P 500 over the past year, with bulls framing the drawdown as a valuation reset and bears pointing to sluggish core growth and a still-elevated earnings multiple as reasons for caution.…
DHR
Danaher Corporation
$200.14
Related headlines
Investment Opinion: Should I buy DHR Today?
We rate Danaher a Hold with a bias toward accumulation on weakness. The core thesis is that DHR is a high-quality life sciences franchise with a fortress balance sheet and 85% recurring revenue, but near-term growth of 3.66% and margin compression limit upside until biotech demand recovers. The analyst consensus is strong buy with a $229.09 average target, implying 14.5% upside, but the wide range ($195-$310) reflects uncertainty. At $200.14, the stock is fairly valued relative to its historical multiples, but a premium to peers on EV/EBITDA (25.3x vs. 15-18x) demands a growth reacceleration that has yet to materialize.
Supporting evidence includes: 1) Forward PE of 21.5x, which is reasonable if EPS doubles to $12.48 as expected; 2) Free cash flow of $5.29B (3.3% yield) and a 0.35 debt-to-equity ratio provide safety; 3) Gross margin of 60.3% and operating margin of 22.6% remain industry-leading; 4) The stock trades 17.6% below its 52-week high and near the low end of its price-to-book range (3.08x). However, revenue growth of 3.66% is well below the 5%+ needed to justify the premium, and the 13.67% underperformance versus the S&P 500 over the past year signals persistent headwinds.
The biggest risks are a continued slowdown in biotech instrument demand, further margin erosion, and integration missteps with Masimo. The rating would upgrade to Buy if revenue growth accelerates above 5% and gross margin stabilizes above 62%, or if the stock pulls back to the $175-$180 support zone. It would downgrade to Sell if revenue growth turns negative or if gross margin falls below 58%. Relative to its own history, DHR is undervalued on a price-to-book basis, but relative to peers, it is overvalued on EV/EBITDA. We see the stock as fairly valued at current levels, with a balanced risk/reward.
Sign up to view all
DHR 12-Month Price Forecast
Danaher presents a balanced risk/reward at current levels. The company's quality franchise, recurring revenue, and strong balance sheet are offset by sluggish growth and margin headwinds. The analyst consensus is bullish, but the wide target range and recent Citigroup downgrade suggest uncertainty. We are neutral with medium confidence, as the stock is fairly valued and lacks a near-term catalyst to drive significant upside. An upgrade to bullish would require evidence of accelerating revenue growth and margin stabilization; a downgrade to bearish would follow a breakdown in biotech demand or a failed Masimo integration.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Danaher Corporation's 12-month outlook, with a consensus price target around $229.09 and implied upside of +14.5% versus the current price.
Average Target
$229.09
0 analysts
Implied Upside
+14.5%
vs. current price
Analyst Count
—
covering this stock
Price Range
$195 - $310
Analyst target range
Danaher is covered by 23 analysts with a consensus recommendation of "strong buy" (recommendation mean of 1.5 on a 1-5 scale where 1 is Strong Buy), and the average price target of $229.09 implies roughly 14.5% upside from the current price of $200.14. The consensus leans clearly bullish, and the estimated EPS average of $12.48 (with a tight range of $12.13 to $12.74) suggests analysts have high confidence in the earnings recovery story, while the estimated revenue average of $33.86 billion (range $33.12 billion to $34.40 billion) implies roughly 4-5% top-line growth. The bullish consensus is notable given the stock's 13.13% YTD decline and 13.67% underperformance versus SPY over the past year, indicating that analysts view the selloff as a disconnect between price and fundamentals rather than a reflection of deteriorating business conditions. The target range is wide, spanning from a low of $195.00 (roughly 2.6% below the current price) to a high of $310.00 (about 54.9% above), a spread of $115 or roughly 50% of the average target, which signals meaningful disagreement about the pace and magnitude of the recovery. The high target of $310 likely assumes successful Masimo integration, a rebound in biotech instrument demand, margin expansion back toward the mid-60s gross margin level, and multiple re-rating toward the upper end of the historical PE band, while the low target of $195 essentially prices in continued sluggish growth, margin compression, and no re-rating. Institutional ratings activity shows a predominantly stable-to-constructive tone: Evercore ISI reiterated Outperform on 2026-07-06, HSBC reiterated Buy on 2026-06-03, and Morgan Stanley, Wells Fargo, Guggenheim, UBS, and Baird all maintained their ratings in April 2026, with the only notable negative action being Citigroup's downgrade from Buy to Neutral on 2026-05-27. The absence of broad downgrades despite the stock's weak performance suggests analysts are treating the pullback as a buying opportunity, consistent with the Motley Fool's July 2026 characterization of the slump as an overreaction to temporary shipment delays, though the wide target spread and the Citigroup downgrade are reminders that conviction is not uniform.
Bulls vs Bears: DHR Investment Factors
The bear case currently has stronger evidence due to DHR's anemic 3.66% revenue growth, margin compression, and significant underperformance versus the S&P 500. However, the bull case rests on a fortress balance sheet, 85% recurring revenue, and a deeply discounted valuation relative to history, with analysts overwhelmingly bullish. The most critical tension is whether the biotech shipment delays are temporary or signal a deeper demand problem; if temporary, the earnings recovery and multiple re-rating could drive substantial upside, but if demand is structurally weaker, the premium valuation is at risk. The wide analyst target range ($195-$310) underscores the high uncertainty. Near-term, the stock is range-bound, and the resolution of biotech order trends and Masimo integration will determine the next leg.
Bullish
- Analyst consensus strong buy: 23 analysts rate DHR a strong buy (mean 1.5) with an average target of $229.09, implying 14.5% upside from $200.14. The high target of $310 suggests 54.9% upside if the recovery accelerates.
- Fortress balance sheet: Debt-to-equity of 0.351 and current ratio of 1.874 provide ample financial flexibility. Interest coverage of 21.3x and $5.29B trailing FCF comfortably fund dividends and M&A.
- Recurring revenue durability: Recurring revenue of $5.03B represents 85% of total revenue, providing a stable base. This high-margin consumables and services mix supports long-term cash flow generation.
- Valuation reset from peak: Price-to-book of 3.08x is near the bottom of its multi-year range (3.03x-4.62x), and the stock trades 17.6% below its 52-week high. The forward PE of 21.5x is reasonable if earnings recover as expected.
Bearish
- Sluggish top-line growth: Revenue grew only 3.66% YoY in Q1 2026 to $5.95B, well below historical norms. This deceleration explains much of the stock's de-rating and raises questions about sustained demand.
- Margin compression: Gross margin fell to 60.34% in Q1 2026 from 66.63% in Q2 2025, and operating margin of 22.58% is below the 26.71% peak in Q4 2024. Mix shifts and shipment delays are pressuring profitability.
- Premium valuation vs peers: EV/EBITDA of 25.3x is a 40-65% premium to the 15-18x typical for diagnostics peers. With only 3.66% growth, this premium is hard to justify without a clear reacceleration.
- Significant underperformance: DHR has lagged the S&P 500 by 13.67% over the past year and 25.21% YTD, with a 33.11% max drawdown. This weak relative strength signals persistent investor skepticism.
DHR Technical Analysis
Danaher is in a choppy, range-bound recovery rather than a clean trend, with the current price of $200.14 sitting roughly 17.6% below its 52-week high of $242.80 and about 24.4% above its 52-week low of $160.93, placing it near the middle-to-upper portion of its annual range. The 1-year price change of just +2.55% badly lags the S&P 500's +16.22% over the same period, producing a relative strength of -13.67% versus the index, which confirms the stock has been a meaningful laggard even as it has stabilized off its lows. The 33.11% maximum drawdown over the trailing year underscores how violent the prior decline was, and the current positioning suggests the stock is in a repair phase rather than a momentum-driven advance. Recent momentum is mixed but modestly constructive: the 3-month change of +11.13% is well ahead of SPY's +3.04% (relative strength +8.09%), yet the 1-month change of -2.75% trails SPY's -1.06% (relative strength -1.69%), indicating the recovery has stalled in the very near term. This divergence between a strong quarter and a soft month is consistent with a temporary pullback within a base-building pattern rather than a trend reversal, especially given the stock's sharp mid-July single-day drop from roughly $201 to $179 on the biotech shipment-delay news. The 6-month change of +6.84% versus SPY's +15.40% (relative strength -8.56%) reinforces that the intermediate trend remains one of underperformance despite the recent bounce. Key technical levels are clearly defined: support sits at the 52-week low of $160.93, with the $175-$180 zone acting as an intermediate floor that has repeatedly attracted buyers, while resistance is anchored at the 52-week high of $242.80, with the $215-$219 area (the August peak near $218.85) serving as the nearer ceiling. A decisive breakout above $219 would signal that the recovery has legs and could open a path back toward the highs, whereas a breakdown below $175 would revive the downtrend and put the $160.93 low in play. With a beta of 0.808, Danaher is roughly 19% less volatile than the broader market, meaning position sizing can be somewhat larger for a given risk budget, but the stock's idiosyncratic event risk (M&A integration, biotech order timing) means its realized volatility has at times exceeded what the beta alone would imply.
Beta
0.81
0.81x market volatility
Max Drawdown
-33.1%
Largest decline past year
52-Week Range
$161-$243
Price range past year
Annual Return
+2.6%
Cumulative gain past year
| Period | DHR Return | S&P 500 |
|---|---|---|
| 1m | -2.7% | -1.6% |
| 3m | +11.1% | +1.3% |
| 6m | +6.8% | +13.9% |
| 1y | +2.6% | +16.3% |
| ytd | -13.1% | +12.1% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
DHR Fundamental Analysis
Danaher's revenue trajectory is modestly growing but decelerating on a sequential basis, with the most recent quarter (period ending 2026-03-27) delivering $5.951 billion in revenue, up 3.66% year-over-year, and net income of $1.029 billion. The multi-quarter trend shows revenue of $6.838 billion in Q4 2025, $6.053 billion in Q3 2025, $5.936 billion in Q2 2025, and $5.741 billion in Q1 2025, indicating a seasonal pattern with a strong year-end quarter followed by a softer first half, and the Q1 2026 print of $5.951 billion is essentially flat versus Q2 2025's $5.936 billion. Segment disclosure shows recurring revenue of $5.031 billion dwarfing nonrecurring revenue of $920 million, a roughly 85/15 split that highlights the durability of the consumables and services base but also means growth is heavily levered to recurring-revenue momentum rather than large one-time instrument placements. The 3.66% YoY growth rate is well below what investors historically expected from Danaher in a normal environment, which explains much of the stock's de-rating and the market's focus on whether biotech funding and China demand can reaccelerate the top line. Profitability remains solid but is compressing at the margin: Q1 2026 gross margin was 60.34%, down from 66.63% in Q2 2025 and 61.42% in Q1 2025, while net income of $1.029 billion produced a net margin of 17.29%, up from 9.35% in Q2 2025 but below the 16.62% recorded in Q1 2025. Operating income of $1.344 billion equates to a 22.58% operating margin, and EBITDA of $1.491 billion represents a 25.05% EBITDA margin, both healthy for the life sciences tools industry but below the 26.71% operating margin posted in Q4 2024. The gross margin volatility (60.3%-66.6% across recent quarters) reflects product mix shifts and the impact of the biotech shipment delays, and the key question for investors is whether the 60%+ gross margin level is a floor or whether competitive and mix pressures push it lower. The balance sheet is a genuine strength: debt-to-equity of just 0.351 and a current ratio of 1.874 indicate conservative leverage and ample liquidity, while trailing free cash flow of $5.291 billion against a $161.9 billion market cap implies an FCF yield of roughly 3.3%. Q1 2026 operating cash flow was $1.322 billion with capex of only $237 million, yielding free cash flow of $1.085 billion, and the company returned $226 million via dividends and $9 million via buybacks in the quarter. ROE of 6.88% and ROA of 3.95% are low in absolute terms and reflect the drag from the large goodwill/intangibles base built through acquisitions, but the interest coverage ratio of 21.3x and cash flow-to-debt ratio of 0.072 confirm that debt service is comfortably manageable and the company can fund both its dividend and tuck-in M&A internally.
Quarterly Revenue
$6.0B
2026-03
Revenue YoY Growth
+3.7%
YoY Comparison
Gross Margin
60.3%
Latest Quarter
Free Cash Flow
$5.3B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is DHR Overvalued?
Because Danaher is solidly profitable with positive net income of $1.029 billion in the most recent quarter, the PE ratio is the appropriate primary metric, and the stock trades at a trailing PE of 45.15x versus a forward PE of 21.53x. The enormous gap between trailing and forward multiples implies the market expects a dramatic earnings step-up, and indeed the consensus forward EPS estimate of $12.48 versus trailing EPS of roughly $4.43 (derived from the 45.15x trailing PE and $200.14 price) implies earnings are expected to more than double, a forecast that hinges on margin recovery, Masimo accretion, and a rebound in biotech demand. The PEG ratio of -9.26 is not meaningful given the distorted trailing earnings base, so the forward PE is the more reliable anchor for valuation work. On a peer-comparison basis, Danaher's 6.59x price-to-sales and 6.55x EV-to-sales sit at a premium to the broader healthcare sector, and its 25.30x EV/EBITDA is elevated relative to the roughly 15-18x typically commanded by diversified medical diagnostics and research tools peers, implying a premium of roughly 40-65% depending on the peer set. That premium is partially justified by Danaher's best-in-class 60.9% gross margin, 20.9% operating margin, and 14.7% net margin, which are at or above the high end of the life sciences tools industry, as well as its 3.3% free cash flow yield and fortress balance sheet with debt-to-equity of just 0.351. However, with revenue growing only 3.66% YoY, the premium is difficult to defend on growth alone, and the market is effectively paying up for the durability and quality of the recurring-revenue base rather than near-term top-line acceleration. Historically, Danaher's PE has ranged from roughly 19.4x (Q4 2022) to 64.5x (Q2 2025), with the current 45.15x trailing multiple sitting in the upper-middle portion of that band but well below the 2025 peak. The price-to-sales ratio of 6.59x is actually near the low end of its historical range, which saw PS ratios of 21.6x-34.3x in 2024 and 21.4x-26.7x in 2022-2023, though those figures reflect a different share count and the pre-Veralto structure, so direct comparison is imperfect. The more telling signal is the price-to-book ratio of 3.08x, which is near the bottom of its multi-year range (3.03x-4.62x), suggesting the market is no longer paying a premium for Danaher's asset base and that the stock has de-rated substantially from its pandemic-era highs.
PE
45.2x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 19x~51x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
25.3x
Enterprise Value Multiple
Investment Risk Disclosure
Danaher's financial risks are moderate but notable. The company carries $0.35 debt-to-equity and a 1.87 current ratio, which are healthy, but its interest coverage of 21.3x and cash flow-to-debt of 0.072 indicate ample capacity to service obligations. However, margin pressure is evident: gross margin fell to 60.34% in Q1 2026 from 66.63% in Q2 2025, and operating margin of 22.58% is below the 26.71% peak in Q4 2024. Revenue growth of just 3.66% YoY, with 85% recurring, means the company is highly dependent on consumables demand; any slowdown in biotech funding or China could further decelerate growth. Additionally, the Masimo acquisition, while financially solid, adds integration risk and could strain management focus if synergies disappoint.
Market and competitive risks are significant given DHR's premium valuation. The stock trades at 25.3x EV/EBITDA, a 40-65% premium to peers, and 45.15x trailing PE, which leaves little room for error. With a beta of 0.808, DHR is less volatile than the market, but its idiosyncratic event risk (e.g., the 12% weekly drop on shipment delays) can cause sharp drawdowns. The life sciences tools sector is highly competitive, with peers like Thermo Fisher and Sartorius vying for the same biopharma budgets. Regulatory headwinds, such as potential drug pricing reforms or changes in NIH funding, could dampen demand. Recent news highlights the Masimo deal as conservative, and the Citigroup downgrade to Neutral on 2026-05-27 signals that not all analysts are convinced.
In a worst-case scenario, a sustained decline in biotech instrument demand, coupled with margin erosion and a failed Masimo integration, could push the stock back to its 52-week low of $160.93, representing a 19.6% decline from the current $200.14. If the bear case target of $195 is breached and sentiment worsens, the stock could test the $160-$175 support zone. The maximum drawdown over the past year was 33.11%, and a similar decline from current levels would imply a price near $134, though that is less likely given the strong balance sheet. A more realistic downside is a retest of the 52-week low, a loss of approximately 20% from current levels.
FAQ
The key risks include: 1) Financial risk: margin compression, with gross margin falling to 60.34% from 66.63% in Q2 2025, and revenue growth of only 3.66% YoY. 2) Competitive risk: intense competition in life sciences tools from Thermo Fisher and Sartorius, which could pressure pricing and market share. 3) Macro risk: a beta of 0.808 means DHR is less volatile than the market, but biotech funding is sensitive to interest rates and economic cycles. 4) Company-specific risk: the Masimo acquisition may not deliver expected synergies, and integration could distract management. The most severe risk is a sustained decline in biotech demand, which could push the stock to its 52-week low of $160.93.
Our 12-month forecast has three scenarios: Bull case (25% probability) targets $242.80-$310, assuming successful Masimo integration, biotech demand rebound, and margin recovery. Base case (55% probability) targets $215-$235, assuming steady 4-5% revenue growth and EPS of $12.48. Bear case (20% probability) targets $160.93-$195, assuming weak biotech demand and margin erosion. The base case is most likely, with the stock gradually recovering toward the analyst average target of $229.09 as earnings visibility improves. The key assumption is that biotech shipment delays are temporary and demand rebounds in the second half of 2026.
DHR appears fairly valued to slightly overvalued on a peer basis but undervalued relative to its own history. The forward PE of 21.5x is reasonable if EPS doubles to $12.48 as expected, but the trailing PE of 45.15x is elevated. EV/EBITDA of 25.3x is a 40-65% premium to diagnostics peers (15-18x), which is hard to justify with only 3.66% revenue growth. However, price-to-book of 3.08x is near the low end of its multi-year range (3.03x-4.62x), suggesting the stock has de-rated significantly. The market is pricing in a successful earnings recovery and Masimo integration; if these fail to materialize, the stock could be overvalued.
DHR is a good buy for long-term investors seeking a quality healthcare franchise with a strong balance sheet and 85% recurring revenue. The stock trades at $200.14, 14.5% below the analyst average target of $229.09, and offers a 3.3% free cash flow yield. However, near-term growth of 3.66% and margin compression are concerns, and the premium valuation (25.3x EV/EBITDA) leaves little room for error. The biggest downside risk is a retest of the 52-week low of $160.93, representing 19.6% downside. For risk-averse investors, waiting for a pullback to the $175-$180 support zone or evidence of accelerating growth would be prudent.
DHR is best suited for long-term investment (minimum 2-3 years) given its quality franchise, 85% recurring revenue, and strong balance sheet. The stock has a beta of 0.808, indicating lower volatility than the market, but it has experienced a 33.11% max drawdown in the past year, so short-term trading carries significant risk. The dividend yield is low at 0.54%, so income is not a primary attraction. Earnings visibility is moderate, with the forward PE of 21.5x implying a doubling of EPS, which may take time to materialize. Short-term traders could exploit the range between $175 and $219, but long-term investors are better positioned to benefit from the recovery and Masimo integration.